Primary Breast Cancer clinical trials

Explore recruiting primary breast cancer clinical trials.

Recruiting primary breast cancer studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Primary Breast Cancer trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

Use of Imatinib to convert triple negative breast cancer into ER-positive breast cancer: I-CONIC

Sweden

Therapeutic exploratory (Phase II) EU CTIS Study details

PREDIX HER2 - Neoadjuvant response-guided treatment of HER2 positive breast cancer. Part of a platform of translational phase II trials based on molecular subtypes

Sweden

Therapeutic exploratory (Phase II) EU CTIS Study details

A randomised phase II trial evaluating the efficacy of a nivolumab monotherapy lead in “window” or commencement of nivolumab concurrently with paclitaxel and carboplatin as neoadjuvant therapy in early stage triple negative breast cancers

Italy

Therapeutic exploratory (Phase II) EU CTIS Study details

A randomised, double-blind, parallel group, placebo-controlled multi-centre Phase III study to assess the efficacy and safety of olaparib versus placebo as adjuvant treatment in patients with germline BRCA1/2 mutations and high risk HER2 negative primary breast cancer who have completed definitive local treatment and neoadjuvant or adjuvant chemotherapy.

Spain, Iceland, Sweden, Netherlands, Poland, Germany +6 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A–BRAVE-Trial. ADJUVANT TREATMENT FOR HIGH-RISK TRIPLE NEGATIVE BREAST CANCER PATIENTS WITH THE ANTI-PD-L1 ANTIBODY AVELUMAB: A PHASE III RANDOMIZED TRIAL

Italy

Therapeutic confirmatory (Phase III) EU CTIS Study details

Unravelling the local and systemic effects of primary surgery and perioperative use of ketorolac and pregabalin in primary breast cancer patients according to adiposity

Belgium

Therapeutic exploratory (Phase II) EU CTIS Study details

Primary Breast Cancer trials by city

Primary Breast Cancer in Toronto Primary Breast Cancer in Vancouver Primary Breast Cancer in Montreal Primary Breast Cancer in Calgary Primary Breast Cancer in Edmonton Primary Breast Cancer in Ottawa Primary Breast Cancer in Winnipeg Primary Breast Cancer in Quebec City Primary Breast Cancer in Hamilton Primary Breast Cancer in Kitchener Primary Breast Cancer in London Primary Breast Cancer in Halifax Primary Breast Cancer in New York Primary Breast Cancer in Los Angeles Primary Breast Cancer in Chicago Primary Breast Cancer in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease